

# Changes in Alanine Aminotransferase in Adults with Severe and Complicated Obesity during a Milk-Based Meal Replacement Programme

**Razk Abdalgwad**

National University of Ireland Galway

**Mohammed Faraz Rafey**

Galway University Hospitals <https://orcid.org/0000-0001-8360-8633>

**Conor Murphy**

Galway University Hospitals

**Iulia Ioana**

Galway University Hospitals

**Paula Marie O'Shea**

Galway University Hospitals

**Eoin Slattery**

Galway University Hospitals

**Colin Davenport**

Galway University Hospitals

**Derek Timothy O'Keefe**

Galway University Hospitals

**Francis Martin Finucane** (✉ [Francis.Finucane@hse.ie](mailto:Francis.Finucane@hse.ie))

Galway University Hospitals <https://orcid.org/0000-0002-5374-7090>

---

## Research

**Keywords:** Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, alanine aminotransferase, severe obesity, milk-based meal replacement programme, bariatric

**DOI:** <https://doi.org/10.21203/rs.3.rs-18620/v2>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

# Abstract

**Introduction:** Excess adiposity is associated with fat accumulation within the liver, and non-alcoholic steatohepatitis (NASH) is highly prevalent in bariatric patients. Elevated alanine aminotransferase (ALT) is associated with prevalent NASH. We sought to determine the influence of a milk-based meal replacement weight-loss programme on ALT levels in adults with severe and complicated obesity.

**Methods:** We conducted a retrospective cohort study of patients who completed a 24-week meal replacement programme, comprised of a weight loss phase followed by weight stabilisation and maintenance phases, each eight weeks long. ALT was quantified using an enzymatic assay with spectrophotometric detection. We examined changes over time in ALT using the non-parametric Wilcoxon signed-rank test and the Friedman test.

**Results:** Of 105 patients, 56 were female, mean age was  $51.2 \pm 11.2$  (range 18.0-71.6) years. There was an unanticipated but transient increase in ALT from 28.0 [20.0, 40.5] iu/l at baseline to 40.0 [26.0, 55.0] iu/l after two weeks ( $p < 0.0005$ ), followed by a gradual reduction to 21.0 [17.0, 28.3] iu/l by 24 weeks ( $p < 0.0005$ ). The overall reductions in ALT were more pronounced in patients who had elevated levels at baseline. Body weight decreased from  $144.2 \pm 28.0$  kg at baseline to  $121.6 \pm 25.4$  kg at 24 weeks ( $p < 0.0005$ ) and body mass index (BMI) decreased from  $50.7 \pm 8.1$  kg m<sup>-2</sup> at baseline to  $43.0 \pm 7.6$  kg m<sup>-2</sup> by 24 weeks ( $p < 0.0005$ ).

**Conclusion:** In adults with severe and complicated obesity undergoing a milk-based meal replacement programme, there was an initial unanticipated rise in ALT in the first two weeks, followed by a gradual overall reduction by 24 weeks. These findings suggest that rapid weight loss secondary to significant caloric restriction might induce a transient deterioration in hepatic steatosis prior to an ultimate overall improvement.

## Introduction

Alanine aminotransferase (ALT) is an enzyme found mainly in the cytosol of hepatocytes, with much higher levels of ALT activity demonstrable in the liver than in other tissues [1-3]. Non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH) is the most common cause of abnormally high levels of ALT [4-8]. NAFLD and NASH are highly prevalent amongst patients with obesity [9-12] and approximately 50% of people affected by obesity have elevated levels of ALT and co-existing NAFLD [13].

Elevated ALT is an independent predictor of prevalent NAFLD and there is a significant association between elevated ALT and NASH and liver fibrosis [14]. Most interventions to reduce body weight in patients who are overweight or obese tend to lead to improvements in NAFLD. For example, after bariatric surgery improvements in NASH and reductions in ALT have been described after 12 months [15]. Conversely, patients with severe obesity undergoing omega loop gastric bypass had a significant increase in ALT whereas those undergoing sleeve gastrectomy or Roux-en-Y gastric bypass had a reduction in ALT [16]. More severe deteriorations in NAFLD after bypass bariatric surgery have also been described, but are the exception rather than the rule [17].

Weight loss interventions based on either increased physical activity, dietary restriction or a combination of the two, have been shown to reduce ALT in meta-analyses [18, 19]. However, intensive caloric restriction such as with a very low-calorie diet has been associated with increased ALT in one study [20].

The underlying mechanistic basis for the heterogeneity in the hepatic physiological response to weight loss interventions has not previously been determined. Nor have previous studies examined serial changes in ALT over time in bariatric patients after initiation of a dietary weight loss intervention. While no substitute for quantifying steatosis with radiological imaging or spectroscopy, changes in liver enzymes could yield valuable insights into the mechanistic basis for improvements in metabolic health with dietary restriction. We have previously described changes in body weight and metabolic characteristics in adults with severe obesity undergoing a milk-based meal replacement programme in our centre [21]. We used milk as the basis for our meal replacement programme for several reasons. It is a relatively low-cost alternative to commercially produced meal replacement supplements, which can be prohibitively cost ineffective [22]. Whey proteins in milk have been shown to attenuate muscle loss [23] and to preserve muscle fibre protein synthesis [24] during very low calorie diets. In men with obesity, milk has been shown to reduce appetite, dietary intake and body weight [25], as well as improving glucose and fat metabolism [26]. A recent trial showed that drinking low fat milk made children feel fuller and eat less later in the day compared to juice or water [27]. We sought to determine the influence of a 24-week milk-based meal replacement programme in patients with severe and complicated obesity on serum ALT as a putative marker of NAFLD.

## Methods

### *Study design, population and setting:*

This was a single-center, retrospective cohort study, conducted in accordance with Strengthening The Reporting of Observational Studies in Epidemiology (STROBE) guidelines [28]. The study population included bariatric patients who were referred to our milk-based meal replacement programme. During the programme, patients attended the bariatric clinic every two weeks for 24 weeks (14 visits in total), met the nurse, dietitian and physician at each visit, had blood tests performed and had weight, height and blood pressure measurements taken. All baseline and follow-up measures for the programme were conducted in the Bariatric Medicine Clinic at the Centre for Diabetes, Endocrinology and Metabolism in Galway University Hospitals (GUH).

### *Inclusion and Exclusion criteria:*

Male and female patients aged 18 years or older, referred to the bariatric service for assessment of severe obesity were eligible for inclusion. Our clinical practice is to define severe obesity as a body mass index (BMI)  $\geq 40 \text{ kg m}^{-2}$  (or  $\geq 35 \text{ kg m}^{-2}$  with co-morbidities such as type 2 diabetes or obstructive sleep apnea syndrome). Patients must have been willing to attend all the 14 scheduled intervention visits. Females of childbearing potential who were pregnant, breast-feeding or intended to become pregnant or were not using adequate contraceptive methods were not considered eligible for the programme. Those with a recent myocardial infarction (within six months), untreated arrhythmia, untreated left ventricular failure, recent cholelithiasis (within the past year), hepatic or renal dysfunction, type 1 diabetes, untreated major psychiatric disorders, eating disorders, cancer, previous bariatric surgery, a BMI  $< 35 \text{ kg m}^{-2}$  or those deemed unlikely to attend for the full programme (e.g. frequent clinic non-attendance) were excluded from the programme. Excess alcohol consumption, defined as more than 21 units per week for men and more than 14 units per week for women, was also an exclusion criterion. Moreover, patients were requested to avoid any alcohol whatsoever during the six-month intervention. Patients with a history of lactose intolerance or allergy to milk or other dairy products were excluded from participation in the milk diet.

### *Ethics approval:*

The study was approved by the Galway University Hospitals' Central Research Ethics Committee in December 2017 (ref CA 1900). As the programme was part of standard clinical care for patients attending our service between 2013 and 2016 and was not a prospective research study, we did not prospectively obtain written informed consent from patients to use their data for research purposes. Considering recent changes in European legislation regarding the use of personal data (the General Data Protection Regulation (GDPR)), we have only used data in this study from the subgroup of patients who agreed to this retrospectively and provided written informed consent.

### *Intervention:*

The milk-based low energy liquid diet (LELD) consisted of three continuous eight-week phases, each with fortnightly visits to the bariatric medicine clinic, as previously described [21]. During the first (weight loss) phase from weeks one to eight inclusive, an exclusively milk-based liquid diet was prescribed, consisting of approximately 2.5 liters per day of semi-skimmed milk (depending on calculated protein requirements [29, 30]) divided in seven portions throughout the day in equal doses, with additional sodium replacement, vitamin, mineral and fiber supplementation, equating to approximately 1200 kcal/day. The dietary composition of 100 mL of semi-skimmed milk included protein (3.5 g), carbohydrate (5 g, of which sugars 5 g) and fat (1.5 g). Throughout this phase, renal and liver profiles were assessed every two weeks and the patients were seen by a physician, bariatric nurse and dietitian at

each visit. During the second phase (weight stabilization) from weeks nine to sixteen inclusive, there was a gradual re-introduction of low-calorie meals from a set menu over eight weeks, according to protocol under the supervision of the bariatric dietitian with fortnightly visits continuing. During the third phase (weight maintenance) from weeks 17 to 24 inclusive, the milk component of the diet was stopped completely and a standard isocaloric diet was restarted, based on individualized meal plans, under the supervision of the bariatric dietitian.

#### *Measurements:*

Weight was measured on a Tanita® scale and height with a Seca® wall-mounted stadiometer, according to departmental standard operating procedures. After an overnight fast, bloods were drawn for glucose, liver, renal and lipid profiles. All blood samples were processed locally in the Galway University Hospitals' Department of Clinical Biochemistry (certified to ISO 15189 2007 accreditation standard). ALT was quantitated using the Roche Cobas® 8000 enzymatic assay with spectrophotometric detection. The decrease in absorbance at 340nm is directly proportional to the concentration of ALT. Inter-assay precision at a mean ALT concentration of 28 iu/l, 121 iu/l and 210 iu/l was 5.4%, 1.6% and 2%, respectively. All of the above measures were performed fortnightly throughout the programme. Normal ALT reference ranges were taken from the American College of Gastroenterology (ACG) clinical guidelines for the evaluation of abnormal liver chemistries (29 to 33 iu/l in men, and 19 to 25 iu/l in women) [31].

SPSS version 25 was used for all statistical analyses. Summary data were presented as means and standard deviations for normally distributed data and medians and interquartile ranges for skewed data, while categorical variables were presented as numbers and percentages.

In addition to analyzing ALT levels across the entire cohort we also classified the patient population into two groups according to baseline ALT levels as 'normal' (patients with normal baseline ALT levels), and 'high' (patients with elevated baseline ALT levels). For baseline characteristics, the independent samples t-test, was used to compare normally distributed variables between groups, while non-normally distributed variables were compared using the Mann-Whitney U test. Pearson's chi square was used to compare proportions of categorical variables.

The Wilcoxon signed-rank test was used to compare changes in ALT levels from baseline to week 2, and from baseline to week 24, respectively. Changes in ALT overtime in weeks 0, 2, 4, 6, 8, 16, and 24 were analyzed using the Friedman test. Changes over time in weight, BMI, excess body weight percentage (EBW%), HbA1c, total, LDL and HDL cholesterol and triglycerides were analysed using repeated measures ANOVA.

## **Results**

### ***Baseline characteristics of study population:***

As described in our previous study [32], 260 patients were enrolled between January 2013 and Oct 2018 into the milk-based meal replacement programme at the Bariatric Medicine clinic in Galway University Hospitals. Of these, 139 (53.5%) completed all 24 weeks of the intervention, with 121 (46.5%) discontinuing the intervention. From 139 completers, 105 (75.5%) agreed to participate in this study and provided written informed consent. Given that 1867 new patients were seen in our bariatric service over the six-year study period, 13.9% of newly referred bariatric patients ultimately participated in our milk programme.

Details of patients' characteristics are shown in Table 1. The average age of participants was 51.1 ±11.2 (range 18.0-71.6) years. 56 (53.3%) were female. The overall median baseline ALT level was 28.0 [20.0, 40.5] iu/l. The 48 patients with a high ALT had no statistically significant differences to the 57 with normal ALT in age, sex, anthropometric or metabolic variables.

### ***Changes in ALT, anthropometrics, and metabolic variables over 24 weeks:***

Table 2 describes the changes in anthropometric variables and ALT levels at weeks 2, 4, 6, 8, 16, and 24 of the programme. From baseline to week 2, ALT levels significantly increased from 28.0 [20.0, 40.5] iu/l to 40.0 [26.0, 55.0] iu/l ( $p < 0.0005$ ), while from

baseline to week 24, there was a statistically significant overall reduction in ALT from 28.0 [20.0, 40.5] iu/l to 21.0 [17.0, 28.3] iu/l ( $p<0.0005$ ). Over time ALT increased from a baseline value of 25 [20.0, 37.3] iu/l to 38 [26.0, 53.5], and 39 [26.0, 60.0] iu/l in weeks 2 and 4, respectively, followed by a significant subsequent reduction to 35 [26.0, 49.0], 32 [23.0, 41.3], 24 [19.0, 34.3], and 21 [17.0, 28.3] iu/l ( $p<0.0005$ ) at weeks 6, 8, 16, and 24, respectively (Table 2; Figure 1a). When we compared patients with normal versus high baseline ALT levels we found that the rise in ALT was greater in those with high baseline ALT, in whom ALT rose from 41.5 [34.3, 63.5] iu/l to 51.0 [41.0, 78.0] iu/l ( $p=0.001$ ) at week 2, then decreased to 27.0 [21.0, 33.5] iu/l ( $p<0.0005$ ) by 24 weeks. Taking a slightly different analytical approach and using the Friedman test (the non-parametric equivalent of analysis of variance), similar results were obtained with ALT increasing from 41.0 [33.0, 62.5] iu/l at baseline to 50.0 [40.5, 85.0], and 50.5 [39.5, 68.3] iu/l at weeks 2, and 4, respectively, reaching 27.0 [21.0, 33.5] iu/l ( $p<0.0005$ ) by 24 weeks. In contrast, those with normal baseline ALT levels had a non-significant increase in ALT from 20.5 [17.0, 24.0] iu/l to 29.5 [20.3, 41.0] iu/l at week 2, followed by a subsequent reduction to 19.0 [16.0, 22.0] iu/l, ( $p<0.0005$ ) by 24 weeks (Table 2; Figure 1b). As described in this cohort previously [32], there were significant reductions in HbA1c in patients with and without type 2 diabetes (table 2).

## Discussion

In a cohort of patients with severe and complicated obesity completing a milk-based meal replacement programme with substantial weight loss over 24 weeks, we found a significant, early and unanticipated rise in ALT that was particularly pronounced in patients who had an elevated ALT at the start of the intervention. This was followed by an overall net reduction in ALT after 24 weeks. To the best of our knowledge this is the first description of a “monophasic” ALT response over multiple time-points with dietary restriction in patients with severe and complicated obesity.

Our findings suggest potential worsening of hepatic inflammation and ectopic fat deposition early in the course of dietary weight loss interventions, prior to longer-term improvements in liver health. However it must be emphasised that this assertion is speculative, because ALT is regarded as a “modestly good at best” indicator of hepatocyte damage in patients with NAFLD [13]. There have been contradictory findings from previous studies on the response of ALT to different types of weight-loss interventions [15-20]. Our findings also suggest that patients with elevated ALT (suggesting a degree of NAFLD) are at higher risk of additional hepatic inflammation, at least during the early stages of dietary restriction-based weight loss interventions.

A recent study of patients undergoing a very low-calorie diet (VLCD) for three weeks prior to bariatric surgery noted a transient rise in ALT [20]. This and other studies [16] have the limitation of measuring ALT levels at two time-points only, whereas we have described short and medium term changes at several time-points, during an acute weight loss phase and then a subsequent period of less intensive weight loss. This approach has allowed us to demonstrate both the acute rise in ALT associated with the early weight loss phase of our LELD intervention as well as the subsequent reduction in ALT levels in the aftermath of significant weight loss once weight had started to stabilise. Ultimately, our findings help to explain the apparently conflicting data on ALT levels and weight loss interventions in the literature to date, suggesting that ALT rises during acute and significant weight loss but that once this phase is over and weight stabilises then ALT levels typically fall below baseline levels. This is consistent with previous findings in a post-hoc analysis of a Danish very low calorie diet intervention (VLCD, ~800kcal/ day) [33] which noted a transient rise in liver transaminases in women but not in men.

The exact mechanisms driving the rise in ALT levels during the early weeks of weight loss interventions are unclear and are beyond the scope of this study. It has previously been demonstrated that during fasting, increased adipose-derived non-esterified fatty acid (NEFA) flux to the liver occurs, promoting intra-hepatic fat accumulation [34-36]. Increased intrahepatic fat, in turn, has been associated with increased generation of fatty acids within the liver via de novo lipogenesis [37]. In a similar manner, studies of male livers following 48 hours of fasting have reported evidence of significant triglyceride accumulation [38]. It may be that states of reduced caloric intake such as those achieved during the weight loss phase of our intervention or after bariatric surgery are associated with an increase in intrahepatic fat concentrations, which in turn may drive increases in ALT levels and potentially NAFLD severity. Once caloric intake and weight has stabilised, this effect may then decrease and intra-hepatic fat accumulation may diminish, leading to an eventual net decrease in ALT levels from baseline.

Aside from fat mobilisation and lipogenesis, another potential mechanism that could lead to increased ALT during the milk diet is the activation of hepatic gluconeogenesis during caloric restriction, as has been demonstrated in mouse studies [39]. Bearing in mind that liver disease was an exclusion criterion for the intervention and that patients were required not to consume any alcohol

throughout the six months, we think that these are unlikely factors to account for the transient rise in ALT. Moreover, incident drug use such as with non-steroidal anti-inflammatory drugs or antibiotics or very strenuous physical activity, while not formally quantified in this study, are unlikely to account for our findings.

The reasons for the relatively larger rise in ALT in patients who had elevated levels at baseline are unclear but may reflect an inherent vulnerability to accumulation of excess intrahepatic lipid at any given level of excess body fat accumulation. This heterogeneity in the relationship between adiposity and metabolic dysfunction is likely to arise from a complex interaction of genetic and environmental factors and needs to be explored further in mechanistic studies, incorporating quantification of insulin sensitivity, fat mass, changes in circulating non-esterified fatty acids and other relevant confounders.

This study has a number of limitations, not least its retrospective nature and its inclusion of patients who completed the milk diet programme, from which there was a very high attrition rate, with no data available on patients who dropped out. Thus, our findings are not generalisable to other patient populations outside of a hospital-based cohort of patients with severe and complicated obesity, nor are they generalisable to other weight loss interventions. Arguably our most important limitation is the use of ALT as a surrogate indicator of NAFLD, as it is relatively non-specific and lacks sensitivity [40]. Again, the use of imaging and histological studies would help to address this limitation in future studies. These were not acquired as part of the routine clinical assessment of our patients enrolling in the milk programme. Of note, previous studies have utilised ALT levels as a surrogate marker of NAFLD [13, 41, 42]. Moreover, we think that our inclusion and exclusion criteria for the milk-based meal replacement programme would have reduced the risk of confounding (for example from excess alcohol consumption), making it more likely that variations in ALT levels within our population reflected changes in hepatic fat accumulation and inflammation. One other limitation is the six-month duration of the study. Future studies could focus on longer-term follow-up, in particular with regards to changes in ALT levels associated with weight regain.

## Conclusions

In adults with severe and complicated obesity undergoing a milk-based meal replacement programme, we demonstrated an initial significant rise in ALT levels over the first eight weeks which was greater in those with elevated ALT levels at baseline. This was followed by an overall reduction in ALT levels during the weight stabilisation and maintenance phases of our programme such that there was a net overall decrease in ALT levels at 24 weeks. Whether these preliminary and exploratory observations are related to changes in liver fat content needs to be determined by imaging studies, but this seems biologically and mechanistically plausible. These results may be of particular relevance to patients with severe hepatic inflammation undergoing acute dietary restriction for weight loss, where vigilance relating to the use of hepatotoxic drugs could be particularly important. The mechanistic factors underlying the heterogeneity in the response of intrahepatic lipid to dietary weight loss warrant further scientific scrutiny.

## Abbreviations

ACEIs: Angiotensin-converting enzyme inhibitor; ACG: American College of Gastroenterology; ARBs: Angiotensin II receptor blockers; ALT: Alanine Aminotransferase; ANOVA: Analysis of variance; BMI: Body Mass Index; DDP4: Dipeptidyl peptidase-4 inhibitors; EBW%: Excess Body Weight percentage; GDPR: The General Data Protection Regulation; GLP1: Glucagon-like peptide 1; GUH: Galway University Hospitals; HbA1c: Glycated haemoglobin; HDL: High Density Lipoprotein; IQR: Interquartile range; LELD: The milk-based Low Energy Liquid Diet; LDL: Low Density Lipoprotein; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis; NEFA: Adipose-derived non-esterified fatty acid; PPAR $\gamma$ : Peroxisome proliferator-activated receptor gamma; SGLT2: Sodium-glucose co-transporter 2 inhibitors; STROBE: Strengthening The Reporting of Observational Studies in Epidemiology; SU: Sulfonylureas; VLCD: Very low calorie diet.

## Declarations

### Acknowledgement

We would like to acknowledge all our patients who participated in this study and to the staff of Centre for diabetes, endocrinology and metabolism for their hard work in delivering this programme successfully.

## Author Contributions

R. Abdalgawad contributed to the study design, conducted data analysis and prepared the manuscript. M.F. Rafey contributed to study design, data collection, conducted data analysis and prepared the manuscript. C. Murphy and I. Ioana contributed to the study design, data collection and revised the manuscript. P. O'Shea processed biochemistry samples, collated metabolic data and revised the manuscript. E. Slattery, C. Davenport and D. O'Keeffe contributed to the data analysis and revised the manuscript. F.M. Finucane conceptualised the study design, led the clinical intervention and supervised the data collection, drafting of the manuscript and the data analysis. All authors have given final approval of the version to be published and agree to be accountable for all aspects of the work.

## Funding

This work was funded by a project grant from Healthy Ireland, a Government of Ireland initiative. F.M. Finucane is funded by a Clinical Research Career Development Award from the Saolta Hospital Group.

## Guarantor

Prof Francis Finucane.

## Availability of data and materials

The data can be made available upon request.

## Ethics approval and consent to participate

The study was approved by the Galway University Hospitals' Central Research Ethics Committee in December 2017 (ref CA 1900). All participants provided written informed consent to participate in the study.

## Consent for publication

Not applicable.

## Competing interests

R. Abdalgawad, M.F. Rafey, C. Murphy, I. Ioana, E. Slattery and P. O'Shea declare that they have no competing interests. C. Davenport, D. O'Keeffe and F.M. Finucane have received honoraria, travel grants and have served on advisory boards for Novo Nordisk, Eli Lilly, Ethicon, Pfizer Inc., Sanofi-Aventis, Astra Zeneca, Merck-Serono, Boehringer Ingelheim, Janssen and Novartis.

## References

1. Liu, C.F., et al., *The associations between liver enzymes and the risk of metabolic syndrome in the elderly*. *Exp Gerontol*, 2018. **106**: p. 132-136.
2. Ferrier, D.R. and R.A. Harvey, *Lippincott's illustrated reviews: biochemistry*. 2014.

3. MacFarlane, I., A. Bomford, and R. Sherwood, *Liver Disease and Laboratory Medicine*. 2000: ACB Venture Publications.
4. Zelber-Sagi, S., et al., *Low serum vitamin D is independently associated with unexplained elevated ALT only among non-obese men in the general population*. *Annals of hepatology*, 2019.
5. Armstrong, M.J., et al., *Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort*. *Journal of hepatology*, 2012. **56**(1): p. 234-240.
6. Burtis, C.A., E.R. Ashwood, and D.E. Bruns, *Tietz textbook of clinical chemistry and molecular diagnostics-e-book*. 2012: Elsevier Health Sciences.
7. Sayiner, M., et al., *Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world*. *Clinics in liver disease*, 2016. **20**(2): p. 205-214.
8. Benedict, M. and X. Zhang, *Non-alcoholic fatty liver disease: An expanded review*. *World journal of hepatology*, 2017. **9**(16): p. 715.
9. Bower, G., et al., *Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology*. *Obes Surg*, 2015. **25**(12): p. 2280-9.
10. Angulo, P. and K.D. Lindor, *Non-alcoholic fatty liver disease*. *J Gastroenterol Hepatol*, 2002. **17 Suppl**: p. S186-90.
11. Dixon, J.B., P.S. Bhathal, and P.E. O'Brien, *Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese*. *Gastroenterology*, 2001. **121**(1): p. 91-100.
12. Gupta, R., et al., *The prevalence of non-alcoholic fatty liver disease and metabolic syndrome in obese children*. *J Pediatr Endocrinol Metab*, 2011. **24**(11-12): p. 907-11.
13. de Luis, D.A., et al., *Relationship of insulin resistance and adipocytokines on serum alanine aminotransferase in presurgical morbid obese patients*. *Eur Rev Med Pharmacol Sci*, 2009. **13**(6): p. 413-8.
14. Praveenraj, P., et al., *Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery*. *Obes Surg*, 2015. **25**(11): p. 2078-87.
15. Lassailly, G., et al., *Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients*. *Gastroenterology*, 2015. **149**(2): p. 379-88; quiz e15-6.
16. Spivak, H., et al., *Omega-loop gastric bypass is more effective for weight loss but negatively impacts liver enzymes: a registry-based comprehensive first-year analysis*. *Surg Obes Relat Dis*, 2018. **14**(2): p. 175-180.
17. Eilenberg, M., et al., *Significant Liver-Related Morbidity After Bariatric Surgery and Its Reversal-a Case Series*. *Obes Surg*, 2018. **28**(3): p. 812-819.
18. Zou, T.T., et al., *Lifestyle interventions for patients with nonalcoholic fatty liver disease: a network meta-analysis*. *Eur J Gastroenterol Hepatol*, 2018. **30**(7): p. 747-755.
19. Orci, L.A., et al., *Exercise-based Interventions for Nonalcoholic Fatty Liver Disease: A Meta-analysis and Meta-regression*. *Clin Gastroenterol Hepatol*, 2016. **14**(10): p. 1398-411.
20. Schwenger, K.J.P., et al., *Non-alcoholic Fatty Liver Disease in Morbidly Obese Individuals Undergoing Bariatric Surgery: Prevalence and Effect of the Pre-Bariatric Very Low Calorie Diet*. *Obes Surg*, 2018. **28**(4): p. 1109-1116.
21. Rafey, M.F., et al., *Effects of a Milk-Based Meal Replacement Program on Weight and Metabolic Characteristics in Adults with Severe Obesity*. *Diabetes Metab Syndr Obes*, 2020. **13**: p. 197-205.
22. Finkelstein, E.A. and E. Kruger, *Meta- and cost-effectiveness analysis of commercial weight loss strategies*. *Obesity*, 2014. **22**(9): p. 1942-51.
23. Verreijen, A.M., et al., *A high whey protein-, leucine-, and vitamin D-enriched supplement preserves muscle mass during intentional weight loss in obese older adults: a double-blind randomized controlled trial*. *The American journal of clinical nutrition*, 2015. **101**(2): p. 279-86.
24. Hector, A.J., et al., *Whey protein supplementation preserves postprandial myofibrillar protein synthesis during short-term energy restriction in overweight and obese adults*. *The Journal of nutrition*, 2015. **145**(2): p. 246-52.
25. Tahavorgar, A., et al., *Whey protein preloads are more beneficial than soy protein preloads in regulating appetite, calorie intake, anthropometry, and body composition of overweight and obese men*. *Nutrition research*, 2014. **34**(10): p. 856-61.



26. van Meijl, L.E. and R.P. Mensink, *Effects of milk and milk constituents on postprandial lipid and glucose metabolism in overweight and obese men*. The British journal of nutrition, 2013. **110**(3): p. 413-9.
27. Mehrabani, S., et al., *Effects of low-fat milk consumption at breakfast on satiety and short-term energy intake in 10- to 12-year-old obese boys*. European journal of nutrition, 2016. **55**(4): p. 1389-96.
28. von Elm, E., et al., *Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies*. Bmj, 2007. **335**(7624): p. 806-8.
29. *A Pocket Guide to Clinical Nutrition*. . 2011: The Parenteral & Enteral Nutrition Group of the British Dietetic Association.
30. Lee, H.A. and T.F. Hartley, *A method of determining daily nitrogen requirements*. Postgraduate medical journal, 1975. **51**(597): p. 441-5.
31. Kwo, P.Y., S.M. Cohen, and J.K. Lim, *ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries*. Am J Gastroenterol, 2017. **112**(1): p. 18-35.
32. Rafey MF, M.C., Abdalgwad R, Kilkelly K, Griffin H, Beatty N, O'Shea PM, Collins C, McGrath R, Hynes M, Davenport C, O'Donnell M, Finucane FM, *Effects of a Milk-Based Meal Replacement Program on Weight and Metabolic Characteristics in Adults with Severe Obesity*. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020. **2020**: p. 197-205.
33. Gasteyer, C., et al., *Effect of a dietary-induced weight loss on liver enzymes in obese subjects*. The American Journal of Clinical Nutrition, 2008. **87**(5): p. 1141-1147.
34. Lattuada, G., et al., *Fasting Whole-Body Energy Homeostasis and Hepatic Energy Metabolism in Nondiabetic Humans with Fatty Liver*. Oxid Med Cell Longev, 2019. **2019**: p. 9796175.
35. Roden, M., *Mechanisms of disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance*. Nature Reviews Endocrinology, 2006. **2**(6): p. 335.
36. Marchesini, G., et al., *Nonalcoholic fatty liver disease: a feature of the metabolic syndrome*. Diabetes, 2001. **50**(8): p. 1844-1850.
37. Lambert, J.E., et al., *Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease*. Gastroenterology, 2014. **146**(3): p. 726-35.
38. Browning, J.D., et al., *The effect of short-term fasting on liver and skeletal muscle lipid, glucose, and energy metabolism in healthy women and men*. Journal of lipid research, 2012. **53**(3): p. 577-586.
39. Hagopian, K., J.J. Ramsey, and R. Weindruch, *Caloric restriction increases gluconeogenic and transaminase enzyme activities in mouse liver*. Experimental Gerontology, 2003. **38**(3): p. 267-278.
40. Fracanzani, A.L., et al., *Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes*. Hepatology, 2008. **48**(3): p. 792-8.
41. Yoo, J., et al., *Relationship between insulin resistance and serum alanine aminotransferase as a surrogate of NAFLD (nonalcoholic fatty liver disease) in obese Korean children*. Diabetes Res Clin Pract, 2008. **81**(3): p. 321-6.
42. De Luis, D.A., et al., *Influence of insulin resistance in obese patients on elevated serum alanine aminotransferase*. Eur Rev Med Pharmacol Sci, 2007. **11**(1): p. 21-5.

## Tables

**Table 1** Baseline characteristics of patients completing the milk programme.

Parameters	All patients	Normal ALT	High ALT	P
N (%)	105 (100%)	57 (54.3%)	48 (45.7%)	
Female	56 (53.3 %)	33 (57.9 %)	23 (47.9 %)	0.307
Age (years)	51.1±11.2	52.9±9.4	49.1±12.8	0.079
Height (m)	1.7±0.1	1.7±0.1	1.7±0.1	0.502
Weight (kg)	144.0±27.6	145.2±27.3	142.6±28.2	0.627
BMI (kg m <sup>2</sup> )	50.6±8.0	51.5±8.2	49.7±8.0	0.254
EBW%	102.5±32.0	106.0±33.0	98.6±31.2	0.254
ALT* (iu/l)	28.0 [20.0,40.5]	22.0 [17.0,24.5]	41.5 [34.3,63.5]	<0.0005
Total cholesterol (mmol/l)	4.6±1.0	4.6±1.0	4.6±1.0	0.786
LDL (mmol/l)	2.5±0.9	2.5±0.9	2.6±0.8	0.442
HDL (mmol/l)	1.2±0.4	1.3±0.4	1.2±0.4	0.131
Triglyceride (mmol/l)	1.8±0.8	1.7±0.6	1.9±1.0	0.151
Diabetes	37 (35.2 %)	19 (33.3 %)	18 (37.5 %)	0.656
HbA1c (mmol/mol)	48.2±15.6	48.1±16.3	48.4±15.0	0.943
<b>Medications</b>				
Metformin	38 (36.2 %)	22 (38.6 %)	16 (33.3 %)	0.576
Insulin	10 (9.5 %)	7 (12.3 %)	3 (6.3 %)	0.294
SU	15 (14.3 %)	10 (17.5 %)	5 (10.4 %)	0.298
DPP4	9 (8.6 %)	6 (10.5 %)	3 (6.3 %)	0.436
SGLT2	6 (5.7 %)	3 (5.3 %)	3 (6.3 %)	0.828
GLP1	18 (17.1 %)	9 (15.8 %)	9 (18.8 %)	0.688
PPARG	1 (1 %)	1 (1.8 %)	-	0.356
ARBs	25 (23.8 %)	12 (21.1 %)	13 (27.1 %)	0.470
ACEIs	30 (28.6 %)	19 (33.3 %)	11 (22.9 %)	0.239
Beta Blockers	31 (29.5 %)	17 (29.8 %)	14(29.2 %)	0.914
Alpha blockers	6 (5.7 %)	3 (5.3 %)	3 (6.3 %)	0.828
Diuretics	31 (29.5 %)	15 (26.3 %)	16 (33.3 %)	0.432
Ezetemibe	4 (3.8 %)	2 (3.4 %)	2 (4.2 %)	0.861

Values are presented as Mean ± SD.

\*Denotes variables that are not normally distributed, presented as median [IQR].

Comparisons between groups were made using Independent samples t-test for normally distributed data, and Mann-Whitney U test for non-normally distributed data.

Proportions with categorical variables were compared using Pearson's Chi-square test.

BMI= Body Mass Index, EBW%= Excess Body Weight Percentage, ALT= Alanine Aminotransferase, LDL= Low Density Lipoprotein, HDL= High Density Lipoprotein, HbA1c= Glycated haemoglobin, SU= Sulfonylureas, DPP4= Dipeptidyl peptidase-4 inhibitors, SGLT2=

Sodium-glucose co-transporter 2 inhibitors, GLP1= Glucagon-like peptide 1, PPARG= Peroxisome proliferator-activated receptor gamma, ARBs= Angiotensin II receptor blockers and ACEIs= Angiotensin-converting enzyme inhibitors.

**Table 2** Changes in anthropometric and metabolic variables over time in patients with normal and high baseline ALT completing the milk programme.

	Week 0	Week 2	Week 4	Week 6	Week 8	Week 16	Week 24	<i>p</i>
ALT (iu/l)*	25 [20.0,37.3]	38 [26.0,53.5]	39 [26.0,60.0]	35 [26.0,49.0]	32 [23.0,41.3]	24 [19.0,34.3]	21 [17.0,28.3]	<0.0005
ALT (iu/l)* <sup>Δ</sup>	41.0 [33.0,62.5]	50.0 [40.5,85.0]	50.5 [39.5,68.3]	41.0 [34.0,67.3]	39.0 [32.0,51.0]	34.5 [25.0,41.3]	26.5 [21.0,36.5]	<0.0005
ALT normal (iu/l)* <sup>#</sup>	20.5 [17.0,24.0]	29.5 [20.3,41.0]	28.5 [20.3,43.0]	27.0 [21.3,38.5]	26.0 [18.3,36.0]	20.0 [17.0,25.0]	19.0 [16.0,22.0]	<0.0005
Weight (kg)	144.2±28.0	137.6±27.4	134.1±27.0	131.0±26.2	128.3±25.6	123.0±25.0	121.6±25.4	<0.0005
BMI (kg m <sup>2</sup> )	50.7±8.1	47.4±10.4	45.4±12.0	44.5±12.0	45.2±7.6	43.2±7.5	43.0±7.6	<0.0005
EBW (%)	103.1±32.4	89.6±42.0	81.6±48.2	78.3±47.4	81.0±30.6	73.0±30.0	71.0±31.0	<0.0005
HbA1c (mmol/mol) <sup>†</sup>	39.3±4.0	37.6±4.0	37.0±4.0	36.3±4.0	36.0±4.2	35.4±3.3	35.3±3.5	<0.0005
HbA1c (mmol/mol) <sup>‡</sup>	67.2±13.3	62.2±13.0	59.0±13.0	56.0±14.2	54.0±15.0	48.5±14.4	48.6±14.1	<0.0005
LDL (mmol/l)	2.6±1.0	2.2±1.0	2.1±0.7	2.2±1.0	2.2±1.0	2.5±1.0	2.6±1.0	<0.0005
HDL (mmol/l)	1.2±0.4	1.1±0.3	1.1±0.3	1.1±0.3	1.1±0.3	1.2±0.3	1.3±0.4	<0.0005
Triglyceride (mmol/l)	1.8±0.7	1.5±0.6	1.4±0.5	1.4±0.5	1.3±0.5	1.3±0.5	1.3±0.5	<0.0005
Total cholesterol (mmol/l)	4.6±1.0	3.9±1.0	3.7±1.0	3.8±1.0	4.0±1.0	4.2±1.0	4.4±1.0	<0.0005

Values are presented as Mean ± SD.


\*Denotes variables that are not normally distributed presented as median [IQR].

<sup>Δ</sup> Denotes variables that represent values higher than normal at the start of the programme.

<sup>#</sup> Denotes variables that represent values that were normal at the start of the programme.

<sup>†</sup> Denote patients without history of type 2 diabetes. <sup>‡</sup>Denote patients with history of type 2 diabetes.

## Figures



**Figure 1**

a. Changes in ALT during milk-based meal replacement programme. Alanine aminotransferase (ALT). All values represent median and interquartile range. P significant for the trend. b. Changes in ALT during milk-based meal replacement programme in patients with high versus normal baseline ALT. Dashed line represents high ALT group. Continuous line represents normal ALT group. All values represent median and interquartile range. The Friedman test was used to analyse changes in ALT over time. P significant for the trend.